Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New migraine drug ubrogepant tested in canadian Real-World study

NCT ID NCT06692881

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study looks at how well the migraine drug ubrogepant works in everyday life for Canadian adults. About 178 participants will take the drug as prescribed and report their ability to function normally after a migraine attack. The goal is to see if ubrogepant helps people get back to daily activities quickly and if they are satisfied with the treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ubrogepant
What this could lead to
If successful, this study could confirm that ubrogepant helps people with migraine return to normal activities quickly after an attack.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows people for 12 weeks, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

178 people

The number who actually took part.

Started

Feb 2025

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants receiving ubrogepant per routine clinical care for the treatment of migraine in Canada.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations). * Adults (≥18 years of age) at time of informed consent. * Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018). * Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms * Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation * Participants willing and able to comply with the requirements of the study. * Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access. Exclusion Criteria: * Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial. * Participants with history of known contraindications to ubrogepant as per local labeling. * Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception * Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies. * History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine

Contacts and locations

Locations

  • 360 Concussion Care /ID# 271972

    Ottawa, Ontario, K1H 7X7, Canada

  • Bayshore Neurology /ID# 280213

    Ottawa, Ontario, K2B 8E8, Canada

  • Burrard Health Center /ID# 271474

    Vancouver, British Columbia, V6Z 2E8, Canada

  • Calgary Headache Assessment and Management Program /ID# 271475

    Calgary, Alberta, T3M 1M4, Canada

  • Centre de Recherche St-Louis /ID# 272843

    Lévis, Quebec, G6W 0M5, Canada

  • Centricity /ID# 271477

    London, Ontario, N6A 2C2, Canada

  • Diex Recherche Sherbrooke /ID# 271677

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Genge Partners /ID# 273302

    Montreal, Quebec, H4A 3T2, Canada

  • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 272031

    London, Ontario, N6A 5W9, Canada

  • Maritime Neurology /ID# 271867

    Halifax, Nova Scotia, B3R 1V9, Canada

  • Neurocentre of Eastern Ontario /ID# 271865

    Kingston, Ontario, K7M 8H9, Canada

  • Royal Jubilee Hospital /ID# 271476

    Victoria, British Columbia, V8R 1J8, Canada

  • Sunnybrook Health Sciences Centre /ID# 276844

    Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.